Blog | HemaCare

Immunotherapy is becoming a promising treatment approach for cancer patients with recurring tumors, and more studies will help to further develop the treatment options.

Surgical resection is still the first-line treatment for solid tumors despite the rate of tumor recurrence with this approach. Surgery to remove tumors provokes wound healing processes that promote local immunosuppressive environments and metastasis. Surgical resection of tumors can also remove beneficial immune cells and factors that could promote targeting and killing of tumor cells. Radio- or chemotherapy as an adjunct to surgery has some limited effects on distant metastasis, but these treatments are associated with significant systemic adverse effects. 

Researchers find that modulating cholesterol metabolism makes CD8 T cells better at fighting cancer.

We all know that too much cholesterol is bad for our health. However, our CD8 T cells beg to differ. If they accumulate more cholesterol inside their plasma membrane, they become better at fighting cancer. This is what the latest research published in the journal Nature shows.

Researchers discover a missing link in the progression of B cell lymphoma.

Diffuse large B cell lymphoma is the most common form of non-Hodgkin lymphoma (NHL), contributing to about 30% of the cases in the United States. It is an aggressive form of NHL that usually presents itself with severe swelling of the lymph nodes at the sites being affected. The most common therapy for the disease is a combined immunotherapy with rituximab and radiotherapy. Secondary therapies are also used for patients who do not respond to the initial therapy, or who relapse after a period of remission.¹

Researchers find that statins can reduce gastric cancer by affecting the main causative bacteria, Helicobacter pylori.

It's a scientist’s dream: to find that an already known medication can treat a second and completely unrelated disease. This is what a research group recently may have found. The cholesterol-lowering drugs, statins, might reduce gastric cancer incidence by affecting the bacteria that causes the cancer.